medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2011, Número 12

<< Anterior Siguiente >>

Ginecol Obstet Mex 2011; 79 (12)


Prevención primaria del cáncer cervicouterino

Idioma: Español
Referencias bibliográficas: 80
Paginas: 794-802
Archivo PDF: 227.06 Kb.


FRAGMENTO

La prevención primaria del cáncer cervicouterino contempla tres vertientes de acción: 1) educación para la salud, cuyo objetivo es modificar hábitos y costumbres que exponen a, o constituyen, factores de riesgo; 2) vacunación contra los VPH-AR más frecuentes, para prevenir la infección cervical que, en ciertas condiciones, será el inicio de la carcinogénesis; y 3) eliminación, en circunstancias precisas, del epitelio metaplásico del cuello uterino (la zona de transformación colposcópica) ya que ahí se originan los cánceres epidermoides que constituyen la mayor parte (~91%1) de los casos de cáncer cervicouterino.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. de Sanjosé S, Quint WGV, Alemany L, et al. Human Papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1038-1056.

  2. Wallboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.

  3. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.

  4. Kousaky LA, Galloway A, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122-163.

  5. Evander M, Edlund K, Gustafsson A, et al. Human papillomavirus infection is transient in young women: A population based cohort study. J Inect Dis 1995;171:1026-1030

  6. Lazcano-Ponce E, Herrero R, Muñoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91:412-420

  7. Moscicki AB, Shiboski S, Broerin J, et al. The natural history of the papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998:132:277-284

  8. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer Lancet 2007;370:890-907.

  9. Burghardt E, Östör AG. Site and origin of the squamous cervical cancer. A histomorphologic study. Obstet Gynecol 1983;62:117-127.

  10. Singer A. The uterine cervix from adolescence to the menopause. Br J Obstet Gynecol 1975;82:82-99.

  11. Walker P, Dexeus S, De Palo G, et al. International terminology of Colposcopy: An updated report from the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2003;101:175-177.

  12. Parkin DM, Bray F. Magnitud de los cánceres atribuibles al VPH. Vaccine 2006;24S3:S3/11-S3/24

  13. Patel S, Chiplunkar S. Host immune responses to cervical cancer. Curr Opinion Obstet Gynecol 2009;21:54-59.

  14. Stanley M. Immune response to human papillomavirus. Vaccine 2006;24(Suppl 1):S16-S22.

  15. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;198:971-978.

  16. Franceschi S, Herrero R, Clifford GM, et al. Variation in the age-specific curves of human papilomavirus prevalence in woman worldwide. Int J Cancer 2006;119:2677-2684.

  17. Zur Hausen H. Cervical carcinoma and human papillomavirus: On the road to preventing a major human cancer. J Intl Cancer Inst 2001;93:252-253.

  18. Sifuentes Álvarez A, Reyes Romero M. Factores de riesgo para cáncer cervicouterino por IVPH: polimorfismo del codón 72 del gen oncosupresor p53 en mujeres que acuden a atención hospitalaria. Ginec Obstet Mex 2003;71:12-15.

  19. Muñoz N, Kato I, Bosch FX, et al. Risk factors for HPV DNA detection in middle-aged women. J Am Sex Trans Dis 1996;23:504-510.

  20. Winner RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. New Engl J Med 2006;354:2645-2654.

  21. Flores YN, Bishai DM, Shah KV, et al. Risk factors for cervical cancer among HPV positive women in Mexico. Salud Publica Mex 2008;50:49-58.

  22. Kiviat N. Natural history of cervical neoplasia: Overview and update. Am J Obstet Gynecol 1996;175:1099-1104.

  23. Castellsagué X, Bosch FX, Muñoz N, et al. Male circumcision, penile human papillomavirus infections, and cervical cancer in female partner. New Engl J Med 2002;346:1105-1112.

  24. Muñoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multi-centric case-control study. The Lancet 2002;359:1093-1101.

  25. Moreno V, Bosch FX, Muñoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-1092.

  26. Castellsagué X, Diaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncology 2011;12:1023-1031.

  27. Parikh S, Brennan P, Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 2003;105:687-691.

  28. Franceschi S, Plummer M, Clifford G, et al. Differences in the risk of cervical cancer and human papillomavirus infection by education level. Br J Cancer 2009;101:865-870.

  29. Ezzati M, Henley J, Lopez AD, et al. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer 2005;116:963-971.

  30. Ward KK, Berenson AB, Breitkopf R. Passive smoke exposure and abnormal cytology in a predominantly Hispanic population. Am J Obstet Gynecol 2011;204:213.e1-e6.

  31. Giuliano A. Cervical carcinogenesis: The role of co-factors and generation of reactive oxygen species. Salud Publica Mex 2005;45(Supl 3):S354-S360.

  32. Schneider V, Kay S, Lee HM. Immunosuppression as a highrisk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol 1983;27:220-224.

  33. Johnson JC, Burnett AF, Willet GD, et al. High frequency of latent and clinical human papillomavirus infections in immunocompromised human immunodeficiency virus-infected women. Obstet Gynecol 1992;79:321-327.

  34. FDA licensure of bivalent human papillomavirus vaccine (HPV2) for use in female and updated HPV vaccination recommendation from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:626-629.

  35. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV 6 virus-like particles in patients with genital warts. J Clin Microbiol 1885;33:2058-2063.

  36. Lacey CJN, Lowndes CM, Shah KK. Magnitud y tratamiento de las patologías no cancerosas asociadas al VPH: patologías asociadas a los VPHs 6 y 11. Vaccine 2006;24S3:S3/35-S3/42.

  37. Stanley M, Lowy DR, Frazer IH. Potential mechanisms for HPV vaccines: underlying mechanisms. Vaccines 2006;24(Suppl 3):S106-S113.

  38. Breiburd F, Kirnbauer R, Hubbert NL, et al. Immunization with virus like particles from cottontail rabbit papilomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-3963.

  39. Kirnbauer R, Chandrachud LM, O’Neil BW, et al. Virus-likeparticles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996;219:37-44.

  40. Villa LL, Ault KA, Giulliano AR, et al. Immunologic response following administration of a vaccine targeting human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particles (VLP) vaccine. Vaccine 2007;25:4931-4939.

  41. Scwartz T, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV 16/18 vaccine: Improving upon nature. Gynecol Oncol 2008;110(Supl 3):S1- S10.

  42. Koutsky LA, Harper DM. Resultados actuales de los ensayos de las vacunas VPH profilácticas. Vaccine 2006;24(S3):S3/122-S3/130.

  43. Nardelli-Haefliger D, Wirthner D, Sciller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Int 2003;95:1128-1137.

  44. Jansen KU, Shaw AR. Human papillomavirus vaccine and prevention of cervical cancer. Annu Rev Med 2004;55:319-331.

  45. Heideman DAM, Snijders PJF, Berkof J, et al. Vaccination against HPV: indication for women and the impact on the cervical screening programs. BJOG 2008;115:938-946

  46. Crosbie EJ, Brabin L. Cervical cancer: problem solved? Vaccinating girls against human papillomavirus. BJOG 2010;117:137-142.

  47. Dopwns LS, Scarcini I, Einstein MH, et al. Overcoming the barriers to HPV vaccination in high-risk populations in the US. Gynec Oncol 2010;117:486-490.

  48. Koutsky LA, for the FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927.

  49. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009;374:301-314.

  50. Brown DR, Kjaer SK, Sigurdson K, et al. The impact of quadrivalent human papillomavirus (HPV types 6, 11, 16, and 18) L1 virus-like particles vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-935.

  51. Herrero R, Human Papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 2009;199:919-922.

  52. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papilloma virus infection in men, cancer other than cervical and benign conditions. Vaccine 2008;26S10:K1-K16.

  53. Palefsky J. Human papiollomavirus and anal neoplasia. Curr HIV/AIDS Rep 2008;5:78-85.

  54. Vargas HVM. Eficacia y seguridad de la inmunización contra la infección del Papiloma Virus Humano. Rev Enfer Tract Genit Inf 2008;2:38-39.

  55. Hildesheim A, Herrero R, Wacholder S, et al. Costa Rican HPV vaccine trial group. Effect of human papillomavairus vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-753.

  56. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009;8:1663-1679.

  57. Secretaría de Salud. Comité Nacional de Cáncer en la Mujer. Lineamientos para la aplicación de las vacunas contra la infección por virus del papiloma humano en el sector privado. 14 páginas. Documento sin fecha.

  58. The American College of Obstetricians and Gynecologists. Committee Opinion. Human Papillomavirus vaccination. Nr 467. Obstet Gynecol 2010;116:800-803.

  59. Bosch FX, Gissman L, Kocken M, et al. European Consensus Statement on “HPV Vaccination and Colposcopy”. Mayo 2010. http://w.w.w.e-f-c.org/

  60. Schwartz TF, Sparczynsi M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-587.

  61. Castellsagué X, Muñoz N, Pitsisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. The Lancet 2009;373(9679):1949-1957.

  62. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009;151:538-545.

  63. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-2145.

  64. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quaderivalent HPV vaccine against infection and disease in males. New Engl J Med 2011;364:401-411.

  65. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:630-632.

  66. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirusassociated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-1510.

  67. Palefsky JM, Gillison ML, Strickler HD. HPV vaccines in immunocompromised women and men. Vaccine 2006;24(S3): S3/140-S3/146.

  68. Garland SM, Ault KA, Gall SA, Paavonen J, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009;114:1179-1188.

  69. Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010;340: c712.doi:10.1136.

  70. Hitt E. Complete HPV immunization rates low in the United States. http://w.w.w.medscape.com/viewarticle718413.

  71. Mulcahy N. Most HPV vaccinations not completed in the urban study. Is text messaging a solution to the problem? http://www.medscape.com/viewarticle/732267.

  72. Neuzil KM, Canh DG, Thiem VD, et al. Immunogenicity and reactogenicity of alternative scheduled HPV vaccine in Vietnam. JAMA 2011;2011;305:1424-1431.

  73. Kreimer AR, Rodríguez AC, Hildelsheim A, et al. Proofof-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2001;103:1444-1451.

  74. Comité Asesor Externo para la Definición de la Política de Vacunación contra el Virus del Papiloma Humano en México. Recomendaciones para la definición de la política de vacunación contra el virus del papiloma humano en México. Salud Publica Mex 2009;51:336-341.

  75. http://www.cnegsr.gob.mx/noticias/186-se-integra-vacunacontra-vph.html (incorporación de la vacuna desde el 01 de enero de 2010 al cuadro básico de inmunizaciones)

  76. Vega M. Universalizan vacuna contra papiloma. Periódico Reforma, Sección Nacional, pág. 2, 15 de julio de 2011.

  77. Modificación a la Norma Oficial Mexicana NOM-014-SSA2-1994 para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer cérvico uterino. Diario Oficial de la Federación. Jueves 31 de mayo de 2007

  78. Ørtof G, Henriksen TB, Hansen ES, et al. After conization of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG 2010;117:258-267

  79. Quenby S. Obstetric management of women after treatment for CIN. BJOG 2010;117:243-244

  80. Bevis KS, Biggio JR. Cervical conization and the risk of preterm delivery. Am J Obstet Gynecol doi:10.1016/j.ajog.2011.01.003




2020     |     www.medigraphic.com